Health Treatment Factory Supply High Quality Pharmaceutical Pirfenidone Powder 53179-13-8 For Anti Fibrosis

CAS:53179-13-8

MF:C12H11NO

MW:185.22

Synonyms:5-Methyl-1-phenylpyridine-2(1H)-one;S-7701;5-methyl-1-phenyl-2-pyridone;5-methyl-1-phenyl-pyridin-2-one;5-methyl-1-phenylpyridin-2-one;5-methyl-1-phenylpyridin-2(1H)-one;Pirfenidone(S-7701,AMR-69);2(1H)-Pyridinone,5-Methyl-1-phenyl-

Melting point:96-97°C

storage temp. Store at RT

solubility DMSO: ≥10 mg/mL, soluble

form solid

Symbol(GHS)

Abstract

Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.

In Europe, pirfenidone is indicated for the treatment of mild-to-moderate idiopathic pulmonary fibrosis. It was approved by the European Medicines Agency (EMA) in 2011. In October 2008, it was approved for use in Japan, in India in 2010, and in China in 2011 (commercial launch in 2014). In October 2014, it was approved for sale in the United States.

In Mexico it has been approved on a gel form for the treatment of scars and fibrotic tissue and has proven to be effective in the treatment of skin ulcers, such as diabetic foot.

Pirfenidone is an anti-inflammatory drug used to treat idiopathic pulmonary fibrosis.Antifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo. Potent scavenger of free radicals and inhibitor of lipid peroxidation.Pirfenidone inhibits collagen production and fibroblast proliferation. It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.

Pirfenidone 0.01 1 mg/ml can suppress the matrix and dose dependent manner serum stimulate uterine fibroids and leiomyoma cell DNA synthesis, the compound has no cytotoxic effect, has no effect on collagen mRNA level also. Pirfenidone in hamster pulmonary fibrosis model can reduce the disease before the collagen I mRNA level enhancement, reduce the level of the lung hydroxyproline and malondialadehyde and lung preserved ammonia acyl hydroxylase activity.

Clinical Application

1. Idiopathic pulmonary fibrosis degeneration
Idio-pathic pulmonary fibrosis (idio-pathic pulmonary fibrosis, IPF) is a cause of unknown, poor prognosis, high mortality of chronic inflammatory interstitial lung disease, and PFD is an anti-inflammatory, anti-fibrosis agents, Can be used for the treatment of IPF.

2. liver fibrosis

3. Renal fibrosis

4. Multiple sclerosis
Multiple sclerosis (multiple sclerosis, MS) is associated with central nervous system and immune-related inflammation and demyelinating disease. The associated immune factors are the activation of stellate cells, glial cells, endothelial cells and lymphocytes, whereas PFD has the ability to inhibit cell activation.

5. Myocardial fibrosis
Cardiovascular diseases such as hypertension, cardiomyopathy and atrial fibrillation can lead to fibrosis of the myocardium, and thus the deterioration of the disease or the development of PFD treatment of sexual levator dystrophy caused by cardiomyopathy, can inhibit myocardial fibrosis, improve Heart function. PFD reduces myocardial remodeling and atrial fibrillation by inhibiting fibrosis.

6. Tumor disease: neurofibroma, uterine leiomyoma, malignant glioma.

7. Prevention of fibrosis after organ transplantation

8. Rheumatoid arthritis
 

Other product List